Crítica de los usuarios - Marcar como inadecuado
AstraZeneca announced the start of anti-cancer drug Vandetanib Phase III clinical study
AstraZeneca in February 26, 2007 announced to take international cooperation, double-blind, parallel, and the way to start anti-tumor drug <a href="http://www.medchemexpress.com/product/Vandetanib.html">Vandetanib</a> Phase III clinical studies, indications are used after failure of first-line anti-cancer drugs for non-small cell lung cancer (NSCLC ). The Phase III clinical study in the United States selected the 20 hospitals, while the other 19 countries to participate in a total of 508 patients involved in clinical research. Vandetanib orally once daily, with reference to drugs is another second-line drugs Alimta. Grouped into Vandetanib and Alimta Ng, or Alimta and placebo. The ultimate indicators include, progressive cancer free survival, overall survival, response rate to anticancer drugs and the reaction period, the role of the disease-related syndromes and security and so on. Vandetanib (trade name Zactima, ZD6474) is a compound similar to the targeting of drugs to combat targeted tumor growth and spread of multiple targets signaling pathways, such as epidermal growth factor receptor tyrosine kinase and vascular endothelial growth factor receptors. Vandetanib in Phase II clinical studies used alone or in combination with other drugs showed effect against non-small cell lung cancer.
Medchemexpress Can provide the above product,its website:<a href="http://www.medchemexpress.com">www.medchemexpress.com</a>
<a href="http://www.medchemexpress.com/product/Fludarabine-phosphate.html">Fludarabine phosphate</a>
<a href="http://www.medchemexpress.com/product/Bardoxolone-methyl.html">Bardoxolone methyl</a>
<a href="http://www.medchemexpress.com/product/NSC-74859.html">NSC 74859</a>
<a href="http://www.medchemexpress.com/product/Sorafenib-Tosylate.html">Sorafenib Tosylate</a>